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ABSTRACT
Maturity-onset diabetes of the young (MODY) is
a heterogeneous group of diseases associated
with gene mutations leading to dysfunction of
pancreatic b-cells. Thirteen identified MODY
variants differ from each other by the clinical
course and treatment requirement. Currently,
MODY subtypes 1–5 are best-studied,
descriptions of the other forms are sporadic.
This article reports a MODY12 clinical case,
caused by a mutation in the gene of the
ATP-binding cassette transporter sub-family C
member 8 (ABCC8), encoding sulfonylurea
receptor 1. Diabetes manifested in a
27-year-old non-obese man with epilepsy in
anamnesis. No evidence of ketosis was present,
pancreatic antibodies were undetectable, and
C-peptide remained within the reference range.
During the initial investigation,
non-proliferative diabetic retinopathy and
elevated albumin excretion rate was revealed.
After 4 months, diabetes was complicated by
pre-proliferative retinopathy and diabetic
macular edema. Recurrent hypoglycemia and
an increase in body weight was observed on
moderate and even small insulin doses. Taking
into account the clinical features and the
presence of diabetes in four generations on the
maternal side, screening for all MODY subtypes
was performed. A mutation in the ABCC8 gene
was found in proband and in his mother. After
the insulin discontinuation, gliclazide modified
release combined with sodium/glucose
cotransporter 2 (SGLT2) inhibitors was started.
This treatment eliminated hypoglycemia and
improved glycemic variability parameters. A
decrease in the amplitude of glucose
excursions was documented by continuous
glucose monitoring. After 3 months of
treatment, glycemic control was still optimal,
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and no hypoglycemic episodes were observed.
The case report demonstrates the clinical
features of ABCC8-associated MODY and the
therapeutic potential of a combination of
sulfonylurea with SGLT2 inhibitor in this
disease.
Keywords: ABCC8; Dapagliflozin; Glucose
variability; Maturity-onset diabetes of the
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INTRODUCTION
Maturity-onset diabetes of the young (MODY) is
a heterogeneous group of disorders caused by
the gene mutations leading to the dysfunction
of pancreatic b-cells. Diagnostic criteria of
MODY include hyperglycemia, usually
manifesting before the age of 25 years,
autosomal dominant inheritance with
transmission across at least three generations,
similar phenotypes of the disease among all
members of a family, and the C-peptide levels
staying within the reference range for years
[1–4]. Confirmation of MODY is complicated
and expensive, but enables to select the
appropriate treatment and conduct genetic
consulting [5, 6]. The real prevalence of
MODY is unknown. According to CH
Lachanse, around 1–2% of diabetes cases can
be classified into this type [1].
At present, it is known that a mutation in
one of 13 genes can cause a certain subtype of
the disease. Subtypes of MODY differ from each
other by their prevalence, clinical picture, and
treatment requirements [1, 7, 8]. Despite
substantial variation in frequency of MODY
subtypes in various populations, the most
prevalent mutations affect genes of hepatocyte
nuclear factor 1a (HNF1A) and glucokinase
(GCK), which cause MODY3 and MODY2,
respectively [9]. The proportion of these
subtypes is up to 90% of all MODY cases [10].
In some European countries, including the
United Kingdom, the Netherlands, and
Denmark, the most common form of
monogenic diabetes is MODY3 (mutation of
HNF1A), but in Spain, Italy, France, Germany,
and the Czech Republic, the predominant form
is MODY2 (mutation of GCK) [11]. The MODY
subtypes 1–5 are the best-studied and most
thoroughly described forms of the disease. The
other subtypes are rare, and the data on their
clinical features and treatment options are
scarce.
In this report, we describe a case of MODY12,
which is caused by a mutation in the
ATP-binding cassette transporter sub-family C
member 8 gene (ABCC8), encoding the
sulfonylurea receptor 1 (SUR1).
CASE PRESENTATION
A 28-year-old Caucasian male, at initial
examination in our clinic (September 2015)
complained of a burning sensation and severe
pain in the legs, numbness of toes, headache,
and blurred vision.
In February 2014, he noticed bothersome
dry mouth, polyuria, and a weight loss (*5 kg
for 4 months). A visit to a local clinic revealed
high plasma glucose (PG), up to 24 mmol/L,
and no signs of ketosis. Besides,
non-proliferative diabetic retinopathy and
increased urinary albumin excretion rate
(microalbuminuria) was detected. Testing for
pancreatic islet antibodies yielded negative
results. The level of C-peptide was 338 pmol/L
(reference range: 298–2350 pmol/L). Type 1
diabetes was diagnosed, and, accordingly,
insulin therapy was initiated with glargine 16
U/day and insulin lispro 4–6 U before main
meals.
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In October 2014, the patient’s vision
deteriorated; ophthalmoscopic examination
revealed pre-proliferative diabetic retinopathy
and diabetic macular edema of both eyes. In the
same month, panretinal laser photocoagulation
was carried out on the right eye, and in February
2015, the procedure was performed on the left
eye.
On insulin therapy, the patient’s body
weight increased by 10 kg, with repeated
episodes of hypoglycemia, and the daily
insulin dose was gradually reduced. In June
2015, the level of glycated hemoglobin A1c
(HbA1c) of 5.1% was recorded. Next month, the
patient had an episode of severe hypoglycemia.
After complete discontinuation of insulin, his
PG level increased up to 15 mmol/L, and the
injections of insulin were restarted.
The patient was the first child of a
21-year-old woman at 35 week of uneventful
pregnancy following spontaneous term
delivery; with a birth weight of 2500 g.
Hyperkinesis, torsion spasm and cramps were
noted in the early neonatal period. Physical and
mental development was normal. From the age
of 3 years, there were several episodes of seizures
lasting 1–2 min with transitional loss of
consciousness (grand mal). Since the diagnosis
of epilepsy had been established treatment with
phenobarbital was administered. The seizures
discontinued at the age of 10 years,
anticonvulsant therapy was withdrawn 3 years
later. No progression of neurological pathology
was observed afterwards. The patient graduated
from a technical community college. No
indication of glucose metabolism disturbances
was revealed in medical records until February
2014.
Diabetes was documented within four
generations on the maternal side (Fig. 1).
Diabetes manifested in all of them in the
fourth or fifth decade of life, and all these
subjects were treated by oral glucose-lowering
agents. On the paternal side, there were
cardiovascular diseases for two generations
(coronary artery disease and sudden death).
On admission to our hospital in September
2015, the patient was taking glargine 13 U at
night and insulin lispro 4 U before lunch and
dinner (no injections were made before
breakfast because of low glycemia). The total
daily insulin dose was 0.3 U/kg.
On examination, height 165 cm, weight
68 kg, body-mass index 25 kg/m2, regular pulse
88 per minute, blood pressure (BP)
140/85 mmHg.
Biochemical analysis revealed moderate
elevation of alanine aminotransferase (78.6
U/L), aspartate aminotransferase (68.2 U/L),
uric acid (422.1 lmol/L), and of
LDL-cholesterol (3.41 mmol/L). Other
parameters were within reference ranges:
creatinine 80.1 lmol/L, urea 6.3 mmol/L,
glomerular filtration rate (Chronic Kidney
Disease Epidemiology Collaboration equation,
2009) 115 mL/min/1.73 m2, bilirubin 14.6
lmol/L, alkaline phosphatase 58 U/L,
c-glutamyltranspeptidase 14 U/L, total
cholesterol 4.2 mmol/L, and triglycerides
0.7 mmol/L. The HbA1c level was 5.9%,
C-peptide 1.35 ng/mL (reference range
0.9–7.1 ng/mL). Testing for hepatitis B and C
markers yielded negative results. Urinary
albumin excretion was 57.3 mg/L. The
reactions for glucose and ketones in the urine
were negative.
Twenty-four-hour BP monitoring revealed
arterial hypertension with average day-time BP
of 157/96 mmHg and nocturnal BP of
155/92 mmHg. Echocardiography showed
intact valves, two additional chords of the left
ventricle, and the ejection fraction 62%.
Ultrasonic Doppler examination indicated
atherosclerosis of brachiocephalic arteries at
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the extracranial level, a hemodynamically
insignificant plaque in the left common
carotid artery spreading to the internal carotid
artery. Ultrasonography of the thyroid gland,
abdominal cavity, and kidneys did not reveal
any pathology. Electromyography showed
pronounced distal sensory neuropathy. The
brain MRI uncovered small chronic
nonspecific foci in basal ganglia and in the
white matter of the hemispheres, atrophic loci
in the periventricular white matter (up to
17 mm), moderate internal hydrocephalus, the
cyst of transparent partition (43 9 12 9 16 mm),
and reduced blood flow through the right
vertebral artery. There was no deterioration
compared to MRI data from 2008.
Considering case features, such as familial
diabetes aggregation, retained C-peptide levels,
Fig. 1 Pedigree
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the absence of islet cell antibodies, and the
obvious signs of insulin overdose on relatively
small doses, we hypothesized MODY.
Whole-exome sequencing was performed on
the genes associated with MODY subtypes 1–13.
Whole exome libraries were prepared with the
Ampliseq Exome Kit (Thermo Fisher Scientific,
Waltham, MA, USA). Sequencing was
performed using the Ion Proton System (Thermo
Fisher Scientific, Waltham, MA, USA). Data
processing pipeline included mapping reads to
the reference human genome (GRCh37) with
the use of Burrows-Wheeler Aligner software. The
single nucleotide variant (CNV) calling was
conducted with Genome Analysis Toolkit. Ion
ReporterTM Software 4.0 (Life Technologies, Thermo
Fisher Scientific, Waltham, MA, USA) was used
for CNV calling. The average exome coverage
was 309.
Mutation Ala1457Thr in the gene ABCC8
was revealed in the proband. The substitution
was confirmed by automatic Sanger sequencing.
The revealed mutation at position 1457 of the
ABCC8 protein is rare and causes a substitution
of alanine with threonine (please see Fig. S1 in
the supplementary material). The online
software PolyPhen-2 (Polymorphism Phenotyping
v2, Boston, Harvard, MA, USA), applied for
prediction of protein structure [12], showed
high probability of an adverse effect of the
Ala1457Thr mutation on the product of the
ABCC8 gene (please see Fig. S2 in the
supplementary material).
In the proband’s mother, we revealed the
same mutation in ABCC8 gene. Despite this,
some phenotypic differences between proband
and his mother were noted. In the mother
arterial hypertension and mild fasting
hyperglycemia (up to 8 mmol/L) was observed
at the age of 30 years. Mild hyperglycemia was
corrected successively on diet alone until
38 years of age (2004). Afterwards, glycemic
control deteriorated, PG increased up to
14 mmol/L, and the therapy with sulfonylurea
was initiated. In September 2015, the level of
HbA1c was 7.6% on the treatment with
gliclazide modified release (MR) 120 mg/day
and vildagliptin 100 mg/day.
Unfortunately, other family members were
not available for clinical evaluation and genetic
testing.
Taking into account the results of
genotyping, we attempted to discontinue
insulin therapy and started the treatment with
gliclazide MR at 60 mg/day. During the first
week on gliclazide, glycemic excursions were
within the range 3.6–12.9 mmol/L. Real-time
continuous glucose monitoring (CGM) with
Medtronic Paradigm MMT-722 and Medtronic
CareLink Pro Software (Medtronic Minimed, Inc,
Northridge, CA, USA) was performed.
Monitoring data on 4–7 days of gliclazide
treatment are shown in Fig. 2. Because of
substantial amplitude of glucose excursions
and a tendency to fasting hypoglycemia,
further increase in gliclazide dose had seemed
inappropriate. Thus, SGLT2 inhibitor
dapagliflozin at 10 mg/day was added. On
combined treatment glycemic excursions
diminished, and no hypoglycemic episodes
were detected by CGM (Fig. 3).
The estimation of glucose variability (GV) at
three therapeutic regimens, including insulin,
gliclazide and gliclazide plus dapagliflozin, was
performed. The GV parameters were derived
from three daily six-point measurements of PG
for each applied treatment option. The Mean
Amplitude of Glucose Excursions (MAGE),
Lability Index (LI), Mean Absolute Glucose
(MAG), Low Blood Glucose Index (LBGI), and
High Blood Glucose Index (HBGI) were
computed with EasyGV calculator (EasyGV
version 9.0 by Nathan R Hill.  University of
Oxford 2010?, UK) [13]. Among these indices,
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MAGE, LI, and MAG reflect the amplitude and
frequency of glucose fluctuations; HBGI
indicates the magnitude of hyperglycemic
excursions; and LBGI estimates the risk of
hypoglycemia [14, 15]. As shown in Table 1,
the notable decrease in GV parameters was
achieved on gliclazide MR and dapagliflozin
combination compared to preceding treatment
with insulin and gliclazide MR alone.
At 3-month follow-up, on treatment with
gliclazide MR 60 mg/day and dapagliflozin
10 mg/day, the level of HbA1c was 6.0%, and
24-h urinary glucose excretion was
719 mmol/day (*40 g/day). No presence of
ketones in the urine was detected.
Self-monitored fasting glucose remained in the
range of 4.3–6.2 mmol/L, no episode of
hypoglycemia was recorded. The body weight
has decreased by 4 kg.
Written informed consent was obtained
from the patient prior to any medical
procedures. Additional informed consent was
obtained for identifying information included
in this article.
Fig. 2 The CGM results on days 4–7 of gliclazide MR treatment. Medtronic CareLink Pro Software (Medtronic Minimed,
Inc, Northridge, CA, USA). CGM continuous glucose monitoring, MR modiﬁed release, Bre breakfast, Lu lunch, Di dinner
Fig. 3 The CGM results on days 2–4 of treatment with
gliclazide MR and dapagliﬂozin. Medtronic CareLink Pro
Software (Medtronic Minimed, Inc, Northridge, CA, USA).
CGM continuous glucose monitoring, MR modiﬁed
release, Bre breakfast, Lu lunch, Di dinner
Table 1 Dynamics of GV parameters
Glucose-lowering therapy MAGE, mmol/L LI, (mmol/L)2/h MAG, (mmol/L)/h LBGI, a.u. HBGI, a.u.
Insulin 5.7 3.0 1.1 5.3 5.4
Gliclazide MR 4.6 2.8 0.8 2.8 4.8
Gliclazide MR ? dapagliﬂozin 2.7 1.0 0.6 0.3 3.4
GV glucose variability, HBGI High Blood Glucose Index, LBGI Low Blood Glucose Index, LI Lability Index, MAG Mean
Absolute Glucose, MAGE Mean Amplitude of Glucose Excursions, MR modiﬁed release, a.u. arbitrary units
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DISCUSSION
The presented case demonstrates the clinical
features of diabetes associated with a rare
mutation in the ABCC8 gene encoding SUR1
(MODY subtype 12). Initially, disease was
misclassified with type 1 diabetes, despite the
absence of ketonuria and antipancreatic
antibodies. The possibility of considering the
case as MODY was supported by the presence of
diabetes within four generations, by
stable levels of C-peptide, and by obvious signs
of overdose on relatively small doses of insulin
in the second year of the clinical course of the
disease.
Genetic testing revealed a mutation in the
ABCC8 gene leading to a substitution of alanine
with threonine in the protein encoded. This
protein is the second subunit of ATP-sensitive
K? channels in pancreatic b-cells, or SUR1. It is
known that closure of ATP-sensitive K?
channels is necessary for glucose-stimulated
secretion of insulin by b-cells, whereas the
opening of these channels inhibits the insulin
secretion. Gene ABCC8 in humans is located on
chromosome 11. Mutations in ABCC8 are
associated with MODY, type 2 diabetes and
gestational diabetes. Some mutations in ABCC8
cause hyperinsulinemia in newborns [16, 17].
Besides, some ABCC8 mutations were revealed
in subjects with neonatal diabetes [18–20].
Recently a mutation in the ABCC8 gene
within three generations of one family was
reported; the phenotype resembles a deficiency
of GCK (MODY2), with ‘‘mild’’ hyperglycemia
that does not require pharmacotherapy [21]. It
was demonstrated that ABCC8 mutations cause
variable clinical phenotypes with glucose
intolerance, overt diabetes, or
insulin-requiring diabetes from a young age to
adulthood. Several factors may explain this
variability, also seen within families, such as
the type and location of the mutation itself or
other modifier genetic and superimposed
environmental factors [22]. In our patient, we
observed the relatively late clinical
manifestation of diabetes (at age of 27 years)
with a dramatic increase in glycemia to high
levels. Surely, the latent course of the disease
prior to clinical manifestation cannot be ruled
out. In proband’s mother, mild hyperglycemia
was corrected successfully for a long time by
diet alone. These observations indicate
heterogeneity of genotype–phenotype
correlations in ABCC8-associated diabetes.
The prognosis of complications in this
subtype of MODY is unknown. In the
observed subject, the appearance of
microvascular complications and, especially,
rapid progression of retinopathy within 2 years
of clinical course of the disease, should be
noted. The combination of hyperglycemia,
dyslipidemia, arterial hypertension and,
possibly, genetic features, could be responsible
for the early manifestation of complications.
Since the early signs of retinopathy and
nephropathy were prior to insulin treatment,
we hardly believe that the emergence of
microvascular complications could be
attributed to hypoglycemic events.
Nonetheless, the role of recurrent
hypoglycemia in progression of retinopathy
and diabetic macular edema development
could not be excluded. The presence of arterial
hypertension, dyslipidemia, hyperuricemia, and
subclinical carotid atherosclerosis may indicate
a higher cardiovascular risk.
Neurological disorders, including epilepsy
and atrophic loci in the periventricular white
matter revealed by MRI, should also be
mentioned. It is a matter of debate whether
these changes resulted from a vascular or
neurodegenerative mechanism, or if they are
residual signs of prenatal brain impairment. At
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the same time, a mechanism specific to the
underlying genetic defect could also be
suspected. The SUR1-regulated ATP-sensitive
K? channels are not constitutively expressed
in the brain, but could be transcriptionally
upregulated in many forms of central nervous
system pathology, including cerebral ischemia,
traumatic brain injury, and subarachnoid
hemorrhage. The channel is linked to
microvascular dysfunction, edema formation,
and accidental necrotic cell death in the brain
[23]. Developmental delay, epilepsy and
neonatal diabetes syndrome represents the
most severe clinical form of permanent
neonatal diabetes caused by ABCC8 mutations
[18]. A milder clinical picture, without
generalized epilepsy and with less severe
developmental delay, was also described [20].
Mild atrophy of frontal–temporal regions of the
brain revealed by MRI was reported in a
5-month-old boy with monoallelic missense
mutation (c.142A[T) in ABCC8 gene [18]. In
our patient the sings of brain impairment
emerged in the early neonatal period, while
diabetes manifested in adulthood. Further
observations are needed to assess the dynamics
of neurological disorders.
Identification of a MODY subtype is crucial
for the choice of adequate treatment. In the
present case verification of the diagnosis by
genetic testing enabled the discontinuation of
insulin therapy, which had produced obvious
adverse effects, such as hypoglycemia and an
increase in body weight. It was demonstrated
that impaired insulin secretion in response to
glucose is a major metabolic feature in adult
ABCC8 mutation carriers [22]. Diabetic patients
with mutations in ABCC8 are usually responsive
to treatment with sulfonylurea [18, 22]. In these
patients, switching from insulin to sulfonylurea
leads to the improvement of metabolic control
[19]. Interestingly, that sulfonylurea in neonatal
diabetes secondary to mutations in
potassium-channel subunits produces
measurable improvements in
neuropsychomotor impairments, which are
greater in younger patients [19, 24].
Furthermore, it was speculated that rather
than a drug that targets both SUR1 and SUR2
isoforms, such as glibenclamide, a SUR1-specific
drug, such as gliclazide, might influence
neurological symptoms more effectively as
only SUR1 isoforms are present in neuronal
KATP channels [18]. In our case, pilot treatment
with gliclazide MR at an average therapeutic
dose turned out to be effective, but was
characterized by large glucose fluctuations and
increased GV. A growing body of evidence
suggests that high GV is a risk factor of
diabetic vascular complications [15, 25].
Taking into account the rapid development of
vascular damage in this patient, it seemed
essential to prevent the episodes of both
hypoglycemia and hyperglycemia and,
thereby, to reduce GV. It was demonstrated
recently that SGLT2 inhibitors decrease GV in
patients with type 2 diabetes [26] and in type 1
diabetes [27]. We observed attenuation of
glucose excursions and reduction of GV
parameters on combined treatment with
gliclazide MR and dapagliflozin in our patient
with MODY.
Data on the use of SGLT2 inhibitors for the
treatment of MODY are scarce. It was reported
recently that dapagliflozin seems to be less
efficient in MODY3 (HNF1A mutations) than
in MODY2 (GCK mutations), that can be
attributed to impaired SGLT2 function [28]. To
the best of our knowledge, we provide here the
first description of treatment with dapagliflozin
in diabetes caused by mutation in the ABCC8
gene. The insulin-independent mechanism of
action of SGLT2 inhibitors makes these agents a
rather promising option for the treatment of
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patients with genetically mediated dysfunction
of b-cells, who are not prone to ketoacidosis,
especially when sulfonylurea effect is
inappropriate.
CONCLUSION
The combination of MODY with prenatal brain
impairment and epilepsy could be a phenotypic
expression of a mutation in the ABCC8 gene,
encoding SUR1. The combined therapy of
sulfonylurea and SGLT2 inhibitors could be
considered as a possible treatment option for
patients with ABCC8-associated diabetes
manifested at adulthood. Personalized
diagnostics and treatment is essential for
young subjects with non-classical diabetic
forms.
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